| Balance Sheets | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Cash and cash equivalents | 21,097 | 15,396 | ||
| Accounts receivable | 7,047 | 9,193 | ||
| Collaboration receivable, billed and unbilled | 282 | 8,178 | ||
| Deferred r&d services, current portion (note 11) | 1,959 | - | ||
| Inventory | 2,304 | 2,522 | ||
| Prepaid expenses and other current assets | 3,586 | 1,492 | ||
| Total current assets | 36,275 | 36,781 | ||
| Property and equipment, net | 225 | 315 | ||
| Operating lease right-of-use asset | 616 | 690 | ||
| Finance lease right-of-use asset | 1,050 | 945 | ||
| Deferred r&d services, non-current portion (note 11) | 2,354 | - | ||
| Other non-current assets | 376 | 376 | ||
| Total assets | 40,896 | 39,107 | ||
| Deferred revenue | - | 481 | ||
| Accounts payable | 1,585 | 2,321 | ||
| Accrued expenses and other current liabilities | 12,600 | 13,101 | ||
| Deferred revenue | 1,564 | - | ||
| Current portion of long-term debt | 12,458 | 12,673 | ||
| Operating lease liability | 335 | 328 | ||
| Finance lease liability | 366 | 318 | ||
| Total current liabilities | 28,908 | 29,222 | ||
| Operating lease liability | 330 | 416 | ||
| Finance lease liability | 629 | 579 | ||
| Derivative liability | 1,762 | 1,796 | ||
| R&d funding liability (note 11) | 4,688 | - | ||
| Long term debt | 21,619 | 24,578 | ||
| Total liabilities | 57,936 | 56,591 | ||
| Common stock, 0.0001 par value 200,000,000 authorized 9,500,549 shares issued and 9,490,035 shares outstanding as of september 30, 2025 and 9,188,513 shares issued and 9,177,999 shares outstanding as of december 31, 2024 | 1 | 1 | ||
| Treasury stock, at cost, 10,514 shares as of september 30, 2025 and december 31, 2024 | 0 | 0 | ||
| Additional paid-in capital | 299,798 | 299,080 | ||
| Accumulated deficit | -316,839 | -316,565 | ||
| Total stockholders deficit | -17,040 | -17,484 | ||
| Total liabilities and stockholders deficit | 40,896 | 39,107 | ||
Verrica Pharmaceuticals Inc. (VRCA)
Verrica Pharmaceuticals Inc. (VRCA)